• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于 Simcyp 基于人群的模拟器中 PBPK 建模的复合文件开发指南。

Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.

机构信息

Simcyp Division, Certara UK Limited, Sheffield, UK.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):805-821. doi: 10.1002/psp4.12791. Epub 2022 Apr 18.

DOI:10.1002/psp4.12791
PMID:35344639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9286711/
Abstract

The Simcyp Simulator is a software platform for population physiologically-based pharmacokinetic (PBPK) modeling and simulation. It links in vitro data to in vivo absorption, distribution, metabolism, excretion and pharmacokinetic/pharmacodynamic outcomes to explore clinical scenarios and support drug development decisions, including regulatory submissions and drug labels. This tutorial describes the different input parameters required, as well as the considerations needed when developing a PBPK model within the Simulator, for a small molecule intended for oral administration. A case study showing the development and application of a PBPK model for ondansetron is herein used to aid the understanding of different PBPK model development concepts.

摘要

Simcyp 模拟器是一个用于群体生理药代动力学(PBPK)建模和模拟的软件平台。它将体外数据与体内吸收、分布、代谢、排泄和药代动力学/药效学结果联系起来,以探索临床情况并支持药物开发决策,包括监管申报和药品标签。本教程描述了口服小分子药物在模拟器中开发 PBPK 模型所需的不同输入参数,以及开发 PBPK 模型时需要考虑的因素。本文使用一个奥丹赛酮 PBPK 模型的开发和应用案例研究来帮助理解不同的 PBPK 模型开发概念。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/a7b74e2e73fa/PSP4-11-805-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/857959d05111/PSP4-11-805-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/b65a75fe9040/PSP4-11-805-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/f630dd2052d3/PSP4-11-805-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/a7b74e2e73fa/PSP4-11-805-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/857959d05111/PSP4-11-805-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/b65a75fe9040/PSP4-11-805-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/f630dd2052d3/PSP4-11-805-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebeb/9286711/a7b74e2e73fa/PSP4-11-805-g002.jpg

相似文献

1
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.用于 Simcyp 基于人群的模拟器中 PBPK 建模的复合文件开发指南。
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):805-821. doi: 10.1002/psp4.12791. Epub 2022 Apr 18.
2
A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator.用于 Simcyp 模拟器中基于生理的药代动力学建模的群体文件开发指南。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1429-1447. doi: 10.1002/psp4.13202. Epub 2024 Jul 18.
3
Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction.应用生理药代动力学平台的选择是否重要?以辛伐他汀处置和药物相互作用为例的研究。
CPT Pharmacometrics Syst Pharmacol. 2022 Sep;11(9):1194-1209. doi: 10.1002/psp4.12837. Epub 2022 Jul 16.
4
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.IMI - 口腔生物药剂学工具项目 - 自下而上 PBPK 预测成功评估第 4 部分:改进数据和建模策略下的预测准确性和软件比较。
Eur J Pharm Biopharm. 2020 Nov;156:50-63. doi: 10.1016/j.ejpb.2020.08.006. Epub 2020 Aug 14.
5
In Silico Prediction of Pharmacokinetic Profile for Human Oral Drug Candidates Which Lack Clinical Pharmacokinetic Experiment Data.缺乏临床药代动力学实验数据的人类口服候选药物药代动力学特征的计算机模拟预测。
Eur J Drug Metab Pharmacokinet. 2022 May;47(3):403-417. doi: 10.1007/s13318-022-00758-9. Epub 2022 Feb 16.
6
Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.通过基于生理的药代动力学模拟血浆浓度-时间曲线来识别药物的肠道损失。
Clin Pharmacokinet. 2008;47(4):245-59. doi: 10.2165/00003088-200847040-00003.
7
Development and Qualification of a Physiologically Based Pharmacokinetic Model of Finasteride and Minoxidil Following Scalp Application.经头皮给药后非那雄胺和米诺地尔的基于生理的药代动力学模型的开发和验证。
J Pharm Sci. 2021 May;110(5):2301-2310. doi: 10.1016/j.xphs.2021.02.016. Epub 2021 Feb 18.
8
Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.生理药代动力学吸收建模和模拟在向美国食品和药物管理局提交新药监管申请中的生物药剂学应用。
AAPS J. 2021 Feb 22;23(2):31. doi: 10.1208/s12248-021-00564-2.
9
Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?基于资格认证的 PBPK 模型构建、评估、验证和应用的平台质量保证及指导原则:为什么、何时、什么、如何以及由谁来做?
Pharm Res. 2022 Aug;39(8):1733-1748. doi: 10.1007/s11095-022-03250-w. Epub 2022 Apr 20.
10
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.IMI - 口服生物药剂学工具项目 - 自下而上的PBPK预测成功评估 第2部分:模拟练习介绍及结果概述
Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2.

引用本文的文献

1
Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals.基于生理的药代动力学(PBPK)模型在药物研发及膳食植物化学物中的应用
Curr Pharmacol Rep. 2025;11(1):45. doi: 10.1007/s40495-025-00427-w. Epub 2025 Aug 8.
2
Prediction of pharmacokinetic/pharmacodynamic properties of aldosterone synthase inhibitors at drug discovery stage using an artificial intelligence-physiologically based pharmacokinetic model.在药物发现阶段使用基于人工智能的生理药代动力学模型预测醛固酮合酶抑制剂的药代动力学/药效学特性。
Front Pharmacol. 2025 Apr 28;16:1578117. doi: 10.3389/fphar.2025.1578117. eCollection 2025.
3

本文引用的文献

1
Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate.开启开源建模工具的辩论:火上浇油还是扑灭健康辩论的火花。
CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):420-427. doi: 10.1002/psp4.12615. Epub 2021 May 1.
2
Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.过去 20 年来,基于生理学的药代动力学模型在药物研发中的发展趋势;对应用、组织和平台的深入分析。
Biopharm Drug Dispos. 2021 Apr;42(4):107-117. doi: 10.1002/bdd.2257. Epub 2021 Jan 17.
3
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug-Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors.
基于生理的药代动力学(PBPK)模型预测非索非那定与CYP1A2抑制剂之间药物相互作用的程度。
J Clin Pharmacol. 2025 Apr 8. doi: 10.1002/jcph.70024.
4
Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs.评估溶解度限制吸收作为预测BCS II/IV类药物食物正效应替代指标的研究
Clin Pharmacokinet. 2025 Mar;64(3):373-385. doi: 10.1007/s40262-025-01473-9. Epub 2025 Feb 3.
5
Prediction of lacosamide concentrations to support dose optimization during pregnancy.预测拉科酰胺浓度以支持孕期剂量优化。
Epilepsia. 2025 Feb;66(2):346-355. doi: 10.1111/epi.18184. Epub 2024 Dec 23.
6
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.用于指导临床试验设计和监管决策的模型驱动药物发现与开发方法:中东和北非地区入门指南
Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27.
7
Key Factors for Improving Predictive Accuracy and Avoiding Overparameterization of the PBPK Absorption Model in Food Effect Studies of Weakly Basic Water-Insoluble Compounds in Immediate Release Formulations.在速释制剂中弱碱性水不溶性化合物的食物效应研究中,提高PBPK吸收模型预测准确性并避免过度参数化的关键因素。
Pharmaceutics. 2024 Oct 12;16(10):1324. doi: 10.3390/pharmaceutics16101324.
8
Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!将新方法(NAMs)数据纳入剂量反应评估:未来已来!
J Toxicol Environ Health B Crit Rev. 2025 Jan 2;28(1):28-62. doi: 10.1080/10937404.2024.2412571. Epub 2024 Oct 10.
9
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?生理药代动力学(PBPK)建模:胃肠道中细胞色素P450 3A4(CYP3A4)表达在准确预测首过代谢中起什么作用?
CPT Pharmacometrics Syst Pharmacol. 2025 Jan;14(1):130-141. doi: 10.1002/psp4.13249. Epub 2024 Oct 2.
10
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report.PBBM 对基础模型、模型验证和应用步骤的考虑:研讨会总结报告。
Mol Pharm. 2024 Nov 4;21(11):5353-5372. doi: 10.1021/acs.molpharmaceut.4c00758. Epub 2024 Sep 30.
Physiologically-Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study.
基于生理的药代动力学模型在药物研发中实现精准给药的作用:人体质量平衡研究的关键作用
Clin Pharmacol Ther. 2021 Jan;109(1):51-54. doi: 10.1002/cpt.2092. Epub 2020 Nov 21.
4
Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models.当将全局敏感性分析方法应用于基于生理学的药代动力学模型时的注意事项和考虑因素。
AAPS J. 2020 Jul 17;22(5):93. doi: 10.1208/s12248-020-00480-x.
5
Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans.昂丹司琼在人体中的血浆和脑脊液药代动力学。
Br J Clin Pharmacol. 2021 Feb;87(2):516-526. doi: 10.1111/bcp.14412. Epub 2020 Jun 30.
6
Biopharmaceutic Extrapolation (IVIV_E) Informed Physiologically-Based Pharmacokinetic Model of Ritonavir Norvir Tablet Absorption in Humans Under Fasted and Fed State Conditions.生物制药外推法(IVIV_E)指导下的利托那韦软胶囊在禁食和进食状态下人体吸收的基于生理的药代动力学模型。
Mol Pharm. 2020 Jul 6;17(7):2329-2344. doi: 10.1021/acs.molpharmaceut.0c00043. Epub 2020 Jun 1.
7
Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake.有机阳离子转运蛋白 1(OCT1)底物在 Oct1/2 敲除小鼠中的药代动力学和肝摄取中 OCT1 介导的物种差异。
Drug Metab Dispos. 2020 Feb;48(2):93-105. doi: 10.1124/dmd.119.088781. Epub 2019 Nov 26.
8
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.基于生理学的药代动力学模型评估膜转运体介导的药物相互作用:当前能力、案例研究、未来机遇和建议。
Clin Pharmacol Ther. 2020 May;107(5):1082-1115. doi: 10.1002/cpt.1693. Epub 2019 Dec 31.
9
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.生物豁免专著:速释固体口服剂型:昂丹司琼。
J Pharm Sci. 2019 Oct;108(10):3157-3168. doi: 10.1016/j.xphs.2019.05.033. Epub 2019 Jun 8.
10
VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays.虚拟体外分布模型,用于机制预测体外毒性试验中化学物质的细胞内浓度。
Toxicol In Vitro. 2019 Aug;58:42-50. doi: 10.1016/j.tiv.2018.12.017. Epub 2018 Dec 29.